The effect between metabolic syndrome and life expectancy after cancer diagnosis: Catalan cohort study.

This study examines remaining life expectancy (RLE) after a cancer diagnosis, focusing on age, sex, cancer type, and metabolic syndrome (MS) components, using data from the SIDIAP database in Catalonia (2006-2017). RLE was analyzed for 13 cancer types, stratified by sex and MS components. The cohort study includes 183,364 individuals followed from diagnosis until death, transfer, or study end (December 2017). RLE at age 68 (median diagnosis age) was calculated based on MS components (0, 1, 2, and ≥ 3). Men aged 68 with 0 MS components had an RLE of 13.2 years, compared to 8.9 years for those with ≥ 3 MS. Women had an RLE of 15.9 years with 0 MS components versus 11.4 years with ≥ 3 MS. RLE varied by cancer type, with the highest RLE in men seen in prostate cancer and in women in non-Hodgkin lymphoma. The lowest RLE for both sexes was in pancreatic cancer. The largest differences between 0 and ≥ 3 MS components were observed in non-Hodgkin lymphoma and the smallest in pancreatic cancer. Increased MS components were associated with reduced RLE in at least 8 cancer types for men and 9 for women. Prevention strategies targeting MS components could increase RLE in cancer patients.
Competing Interests: Declarations. Ethics approval and consent to participate: This study adheres to both national and international guidelines, including the Declaration of Helsinki and Principles of Good Research Practice. In compliance with European and Spanish laws regarding confidentiality and data protection ([EU] 2016/679), all data within SIDIAP is consistently pseudo-anonymized. Hence, obtaining consent from the participants was deemed unnecessary and was waived by the Clinical Ethics Committee at IDIAPJGol. To establish a connection with the CMBD database, SIDIAP utilizes a third-party service to maintain confidentiality. Approval for the study protocol was granted by the Clinical Research Ethics Committee of IDIAPJGol (P17/212) on November 29, 2017. Anonymity and confidentiality of data and medical records were ensured throughout, following the guidelines outlined in the Organic Law 15/1999 on the Protection of Personal Data ( http://www.boe.es/boe/dias/1999/12/14/pdfs/A43088-43099.pdf ). Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
(© 2025. The Author(s).)